**VectorBuilder**, renowned for its comprehensive gene delivery services, and **Sartorius**, a prominent international partner in life sciences and biopharmaceuticals, have formalized a strategic collaboration agreement. This partnership aims to enhance gene vector and mRNA bioprocess services, expediting innovative biopharmaceutical projects from development to clinical application.
With a history of fruitful collaboration, Sartorius and VectorBuilder are poised to broaden the scope of their cooperation. The agreement encompasses several initiatives: co-developing cutting-edge downstream processes for cell and gene therapies, optimizing the commercial production and development platforms for GMP-compliant mRNA, plasmid, and viral vectors, enhancing sustainability initiatives, and regularly exchanging and training talent from both organizations. Additionally, VectorBuilder will spearhead advancements in new modality applications.
**Sarah Wang**, head of Sartorius China, emphasized, “Sartorius prioritizes customer-driven innovation, underlying our offerings and services. This synergistic partnership promises to deliver groundbreaking solutions that improve efficiency and quality for biomedical endeavors, fostering global customer growth and contributing to life sciences advancements.”
In agreement, **Dr. Bruce Lahn**, VectorBuilder’s founder and chief scientist, highlighted, “At the core of VectorBuilder is innovation. Partnering with Sartorius amplifies our ability to provide advanced gene delivery solutions globally, benefiting both researchers and the pharmaceutical industry. We’re thrilled to merge expertise to evolve a robust biopharmaceutical landscape.”
**Michaela Pischke**, Head of Business Area Separation Technologies, mentioned, “Collaborating with VectorBuilder allows us to utilize our combined expertise in downstream processing, minimizing time to market and ultimately saving lives. Kudos to our China team for laying the foundation to fortify this partnership.”
The two companies are committed to exploring the expansive possibilities within cell and gene therapies, hastening the transformation of research breakthroughs into life-saving medical treatments.
Sartorius stands as a pivotal international ally in life sciences and biopharmaceuticals. Its Bioprocess Solutions division offers a diverse product range emphasizing single-use solutions, supporting the efficient, safe, and cost-effective production of biotech drugs, vaccines, as well as cell and gene therapies.
VectorBuilder positions itself as a global front-runner in gene delivery technologies. Trusted by numerous labs and biotech/pharma entities globally, VectorBuilder offers comprehensive design, development, and optimization services for gene delivery solutions across various stages from basic research to clinical applications.